Day 2 (Agenda is subject to change)Tuesday, 4 November 2025

Location: Room 1

From early development through to commercial manufacturing, service providers play an increasingly pivotal role in accelerating biopharma innovation. No longer behind-the-scenes, CDMOs, CROs, and enabling technology platforms are now strategic partners in development. This session brings together leaders from across the services spectrum to discuss how service providers provide critical expertise, infrastructure, and scalability, and contribute to value creation, derisking development timelines, and enable flexible go-to-market strategies. The panelists will explore how partnerships between biotech, pharma, and service providers have evolved, and what trends are shaping the future. As the ecosystem continues to shift toward greater specialization and collaboration, this panel will offer insights into how service providers can be powerful allies in building resilient, agile, and capital-efficient development strategies.

Location: Room 1

This ever-popular session takes a deep dive into the current state of the life sciences industry with the expertise of today’s leading pharma dealmakers and venture investors. Join this engaging discussion to learn how to navigate the current climate of the biotech industry.

Location: Room 1

After years of underinvestment, women’s health is commanding attention and capital. This session will explore the growing momentum behind women’s health as a high-impact investment category and therapeutic frontier, including the recent Series A financing round raised by ReproNovo. Hear from leading industry experts as they dive into the evolving scientific, clinical, and business landscape driving breakthroughs in reproductive health, discuss the signals indicating that women’s health is moving from niche to necessary and understand how stakeholders can ensure the delivery of long-overdue health equity and commercial returns.

Join us for a forward-looking conversation at the intersection of science, funding, and unmet need—where the next generation of women’s health solutions is being shaped.

Location Room 1

The rare disease space continues to be a frontier of high unmet need—and high innovation. This session convenes leading voices to explore how scientific precision, strategic partnerships, capital and novel business models are converging to accelerate drug development in rare conditions. Through real-world insights and case studies, the panelists will discuss how companies are navigating the complexities of clinical development, commercialization in ultra-targeted markets and how to build sustainable pipelines in the face of regulatory, reimbursement, and patient access challenges. Join us for a dive into what makes a rare disease company fundable today and the models, milestones, and mindsets shaping the future of rare disease innovation.

Location: Room 1

Immunology stands as a cornerstone of therapeutic innovation, influencing nearly every major therapeutic area. This panel will delve into next-generation approaches to immune diseases, spotlighting groundbreaking advancements and emerging trends which are paving the way for more effective and targeted therapies. Further, unravel the latest deals and the dynamic momentum of partnerships driving progress in the field and understand how strategic collaborations between pharma, biotech, and academia are accelerating innovation and overcoming translational challenges, to address some of the most pressing challenges in healthcare.

Location: Room 1

Neuroscience has long been considered “high risk,” but the field is experiencing renewed momentum, fueled by modality-enabled breakthroughs and innovative pipeline design strategies. This session explores how precision neuroscience, risk-sharing models, and strategic partnerships are transforming brain research and therapeutic development. The panelists will also highlight cutting-edge advancements in treatments for neurological disorders such as Alzheimer’s disease, Parkinson’s disease etc., and provide valuable insights into emerging trends, investment opportunities, and collaborative models that are reshaping the neuroscience landscape.

Location: Room 2

In biotech partnering, everyone talks about being the preferred partner - but how often do we act that way? In a world where "we'll circle back" can mean silence, and ghosting has become a silent industry norm, just getting a response from a pharma partner can feel like a win. This session brings together investors, pharma dealmakers, and biotech executives to explore the real value of candor in a sector where vague feedback and polite deflections waste time and stall innovation. From pitch meetings to scientific evaluations, we'll unpack how direct dialogue with real feedback can build better partnerships, faster decisions, and less churn for all parties. Clear communication is a win-win for investors, pharma and biotech companies, so why is it an exception and not the norm? Expect real talk, practical tactics and ideas, and no sugarcoating— just straight-up insights into creating a culture of clarity in biotech investment and dealmaking. Isn’t it overdue?

Location: Room 2

The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe audience. A panel of esteemed judges will evaluate the pitches and select the winners.